iPlacenta: ​A European Union Horizon 2020 innovative training network (ITN)

The principal research aim of iPLACENTA is to improve our ability to study, model and visualise the placenta. This will contribute to developing diagnostic tests and therapies for pregnancy complications such as preeclampsia and intrauterine growth restriction (IUGR). Placental defects are thought to be the cause of many major pregnancy complications, such as preeclampsia and intra-uterine growth restriction. Preeclampsia affects between 5 and 8 out of every 100 pregnant women and claims the lives of 76,000 mothers and 500,000 babies annually. Intrauterine growth restriction affects 60,000 births across the EU per year. This is the most common factor for stillborn babies. Yet the low prediction rate means that it often leads to the pre-emptive induction of labour at a premature stage, when it could have been delayed. For the mothers and children that survive preeclampsia and intrauterine growth restriction, there are life-long serious cardiovascular and neurological consequences.

Web page: https://www.iplacenta.eu/

Funding codes:
  • Marie Skłodowska-Curie grant agreement No. 765274
Funding details:

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765274.

Powered by
Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH